|
Jan 22
|
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
|
|
Jan 22
|
Gilead Stock Tumbles on Cancer Drug Disappointment
|
|
Jan 22
|
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
|
|
Jan 22
|
Gilead Sinks After Lung Cancer Drug Fails to Improve Survival
|
|
Jan 22
|
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
|
|
Jan 22
|
BioNTech challenges AstraZeneca with breast cancer precision drug trial
|
|
Jan 22
|
The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific
|
|
Jan 21
|
The total return for AstraZeneca (LON:AZN) investors has risen faster than earnings growth over the last five years
|
|
Jan 19
|
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
|
|
Jan 19
|
Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca
|
|
Jan 19
|
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
|
|
Jan 19
|
Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?
|
|
Jan 18
|
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
|
|
Jan 16
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
Jan 16
|
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn’t One.
|
|
Jan 16
|
Trending tickers: Apple | Tesla | AstraZeneca | Hugo Boss
|
|
Jan 15
|
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca
|
|
Jan 12
|
Astrazeneca (AZN) Laps the Stock Market: Here's Why
|
|
Jan 12
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Jan 11
|
Here's Why Astrazeneca (AZN) Fell More Than Broader Market
|